Catalyst says Phase 1 study shows vamorolone avoids significant immunosuppression at clinical doses

Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc.

CPRX

0.00
  • Catalyst Pharmaceuticals released topline Phase 1 results for vamorolone in healthy volunteers on June 30, 2026; no future presentation was disclosed.
  • Results supported expected steroid-like activity at clinical doses, without signs of meaningful immunosuppression.
  • Switching data versus deflazacort indicated similar overall steroid effects, with a cleaner immune profile for vamorolone.
  • Higher, above-label dosing showed immunosuppressive effects, signaling risk mainly at supratherapeutic exposure.
  • Readout supports current labeled dosing in Duchenne muscular dystrophy, with potential to broaden development into other chronic inflammatory rare diseases.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Catalyst Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300803PRIMZONEFULLFEED9754372) on June 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.